Krystal Biotech, Inc. $KRYS Shares Newly Purchased by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,500 shares of the company’s stock, valued at approximately $1,829,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $1,554,113,000. William Blair Investment Management LLC purchased a new position in shares of Krystal Biotech during the second quarter valued at approximately $211,909,000. Jupiter Topco LLC purchased a new position in shares of Krystal Biotech during the second quarter valued at approximately $95,387,000. Bank of America Corp DE bought a new position in shares of Krystal Biotech during the second quarter valued at approximately $95,308,000. Finally, First Trust Advisors LP lifted its stake in Krystal Biotech by 42.9% in the first quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after acquiring an additional 105,245 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Zacks Research cut shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Bank of America upped their price objective on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada dropped their target price on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $375.00.

Insider Transactions at Krystal Biotech

In other news, Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.

Krystal Biotech Stock Up 0.8%

Shares of KRYS stock opened at $308.81 on Thursday. The stock has a market cap of $9.15 billion, a price-to-earnings ratio of 41.90 and a beta of 0.56. The business’s fifty day moving average is $329.35 and its 200 day moving average is $309.43. Krystal Biotech, Inc. has a twelve month low of $198.02 and a twelve month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The business had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. Equities research analysts expect that Krystal Biotech, Inc. will post 7.74 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.